<DOC>
	<DOCNO>NCT01353833</DOCNO>
	<brief_summary>IL-2 inducer regulatory T cell ( Treg ) , population lymphocyte fail control autoimmune destruction beta-cells patient Type 1 Diabetes ( T1D ) . The investigator recently show low dose IL-2 well tolerate patient autoimmune disease . The investigator aim use IL-2 induce/stimulate Treg T1D patient . This study investigate dose effect relationship low dose IL-2 Treg induction optimize risk benefit ratio treatment T1D . By Treg induction , investigator aim protect remaining/regenerating β-cells autoimmune destruction , thus improve even cure T1D .</brief_summary>
	<brief_title>Dose-effect Relationship Low-dose IL-2 Type 1 Diabetes</brief_title>
	<detailed_description>Rationale : Type 1 diabetes ( T1D ) result autoimmune destruction beta-pancreatic cell regulatory T cell ( Treg ) fail control . This part due deficit production , response , interleukin 2 ( IL-2 ) . This cytokine essential Treg development , survival function . Importantly , IL-2 also contribute activation effector T cell ( Teff ) , IL-2/IL-2 receptor signal transduction threshold much low Treg Teff . Thus low-dose IL-2 could specific Treg inducer/stimulator . The investigator recently show low-dose IL-2 could cure recent onset diabetes NOD mouse develop spontaneous diabetes consider best model human T1D . A 5-day treatment IL-2 could cure 30 % mouse versus 0 % control . With premise , investigator propose explore Treg induction could obtain patient may deficit production , response , IL-2 . Defining dose effect relationship low dose IL-2 Treg induction optimize risk benefit ratio IL-2 T1D . Principal objective : To define dose-effect relationship low dose IL-2 Treg induction patient recent onset diabetes Evaluation Criteria : - Efficacy Kinetic variation Treg proportion within CD4+ T cell peripheral blood Day+0 Day+60 . - Tolerance Evaluation clinical exam , laboratory test monitor side effect . The criterion terminate study occurrence one serious unexpected side effect month follow IL-2 first administration least 2 patient . Study plan : After inclusion ( Day0 ) , patient receive 5-day course IL-2 placebo . Patients randomize 4 arm receive either placebo , IL-2 dose 0,33 - 1 3 million UI/day . Laboratory follow-up peripheral blood T cell subset perform D0 D6 ( daily ) , D15 , D22 D60 immunophenotyping transcriptomics . Tolerance evaluate D0-6 , D15 , D22 D60 . Methodology : Double blind placebo control randomize study , 4 parallel group . Patients T1D autoimmune origin attest presence auto-antibodies ( least one : anti-islet , anti-GAD , anti-IA2 anti-ZnT8 ) , diagnostic inferior equal 24 month . Study length : Study length = 9 month Patient participation = 2 month Inclusion period = 6 month</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age [ 1850 ] year ; With T1D : Treated insulin ≤ 2 year , With least one autoantibody among : antiislet , antiGAD , antiIA2 , antiZnT8 ; No clinically relevant abnormal value hematology , biochemistry , liver kidney function Lymphocyte [ 10004000 ] / mm3 Informed consent sign patient investigator intervention necessary trial . Contraindications IL2 : Hypersensibility IL2 excipients , Severe cardiopathy Ongoing infection require antibiotherapy , O2 Saturation ≤ 90 % Severe impairment vital organ Previous organ allograft Non authorize concomitant treatment : i.e . immunomodulators , cytotoxic , drug modify glycemia Cancer progressing cure less 5 year except primary basal cell carcinoma carcinoma situ uterine cervix . Participation another clinical investigation &lt; 3 month Pregnant lactate woman Male female age procreation without efficient contraception study No affiliation National Health Insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>